Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $53.40
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has received a consensus rating of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target […]
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has received a consensus rating of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target […]
